上皮钠通道
化学
囊性纤维化
阿米洛利
临床试验
药理学
内科学
钠
医学
有机化学
作者
Bodo Betzemeier,Clemens Braun,Peter Sieger,Armin Heckel,Günter Linz,Brian Linehan,Thomas Veser,Dieter Wiedenmayer,Jörg T. Kley
标识
DOI:10.1016/j.ejmech.2023.116038
摘要
Lung selective inhibition of the endothelial sodium channel (ENaC) is a potential mutation agnostic treatment of Cystic Fibrosis (CF). We describe the discovery and development of BI 1265162, the first ENaC inhibitor devoid of the amiloride structural motif that entered clinical trials. The design of BI 1265162 focused on its suitability for inhalation via the Respimat® Soft Mist™ Inhaler and a long duration of action. A convergent and scalable route for the synthesis of BI 1265162 as dihydrogen phosphate salt is presented, that was applied to support clinical trials. A phase 2 study with BI 1265162 did not provide a clear sign of clinical benefit. Whether ENaC inhibition will be able to hold its promise for CF patients remains an open question.
科研通智能强力驱动
Strongly Powered by AbleSci AI